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Abstract
Background: In this study several tumor-related volumes were assessed by means of a computer-based
application and a survival analysis was conducted to evaluate the prognostic significance of pre- and postoperative
volumetric data in patients harboring glioblastomas. In addition, MGMT (O
6-methylguanine methyltransferase)
related parameters were compared with those of volumetry in order to observe possible relevance of this molecule
in tumor development.
Methods: We prospectively analyzed 65 patients suffering from glioblastoma (GBM) who underwent radiotherapy
with concomitant adjuvant temozolomide. For the purpose of volumetry T1 and T2-weighted magnetic resonance
(MR) sequences were used, acquired both pre- and postoperatively (pre-radiochemotherapy). The volumes
measured on preoperative MR images were necrosis, enhancing tumor and edema (including the tumor) and on
postoperative ones, net-enhancing tumor. Age, sex, performance status (PS) and type of operation were also
included in the multivariate analysis. MGMT was assessed for promoter methylation with Multiplex Ligation-
dependent Probe Amplification (MLPA), for RNA expression with real time PCR, and for protein expression with
immunohistochemistry in a total of 44 cases with available histologic material.
Results: In the multivariate analysis a negative impact was shown for pre-radiochemotherapy net-enhancing tumor
on the overall survival (OS) (p = 0.023) and for preoperative necrosis on progression-free survival (PFS) (p = 0.030).
Furthermore, the multivariate analysis confirmed the importance of PS in PFS and OS of patients. MGMT promoter
methylation was observed in 13/23 (43.5%) evaluable tumors; complete methylation was observed in 3/13
methylated tumors only. High rate of MGMT protein positivity (> 20% positive neoplastic nuclei) was inversely
associated with pre-operative tumor necrosis (p = 0.021).
Conclusions: Our findings implicate that volumetric parameters may have a significant role in the prognosis of
GBM patients. Furthermore, volumetry could help not only to improve the prediction of outcome but also the
outcome itself by identifying patients at high risk of treatment failure and, thus, seek alternative treatment for these
patients. In this small series, MGMT protein was associated with less aggressive tumor characteristics.
Background
Glioblastoma (GBM) is still one of the most uniformly
fatal tumors. Although various radiotherapy techniques
and altered fractionation schedules [1-6], as well as dif-
ferent chemotherapeutic regimens [7,8] have been
implemented, the overall survival of glioblastoma
patients remains rather poor, with a median survival of
12-18 months. A major problem concerning the study
of these patients is the identification of robust prognos-
tic parameters. Evaluation of p r o g n o s t i cf a c t o r si sv i t a l
to improve research pursuing new therapies for glioblas-
tomas, since a better randomization or stratification into
various treatment arms can be achieved.
In brain tumor research, the importance of tumor size
as one of them has long been debated. In contrast to
other tumor sites (head and neck, ovary, uterine cervix,
stomach), there are numerous studies [9-15] marking
out tumor size as a prognostic factor or as a predictor
of outcome of certain therapies.
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included, involves radiotherapy with concomitant
administration of the alkylating agent temozolomide
[16]. The addition of temozolomide seems to benefit
patients with tumors exhibiting methylated CpG islands
at the promoter and enhancer regions of the gene
encoding for O
6-methylguanine methyltransferase
(MGMT) [17,18]. The assessment of MGMT promoter
methylation is currently considered as mandatory for
patient selection in clinical trials [19]; testing for
MGMT methylation is nevertheless still not officially
requested as a marker predictive for temozolomide
response in clinical practice, mainly due to methodologi-
cal shortcomings [20] and to the lack of alternative
treatment options in patients without MGMT promoter
methylation [16]. In addition, the prognostic significance
of MGMT promoter methylation regardless of therapeu-
tic intervention remains controversial [17,21].
In the present study, we explored the prognostic sig-
nificance of several volumetric parameters, for overall
survival and progression-free survival in patients harbor-
ing glioblastoma and treated postoperatively with radio-
therapy and temozolomide. Our purpose was to decide
if there is still a role of the volumetric MR (magnetic
resonance) data in prognostic categorization of glioblas-
toma patients. This could be of crucial importance in
designing future studies with more intensive therapeutic
schemes. In addition, we compared MGMT related
parameters with those of volumetry in order to observe
possible implications of this molecule in tumor develop-
ment and, subsequently, treatment response.
Methods
Patients
In this single-institutional prospective study, 65 patients
older than 18 years of age with newly diagnosed and histo-
logically proven glioblastoma (World Health Organization
[WHO] grade IV astrocytoma), who attended clinics from
July 2005 to August 2007 of Radiation Oncology in Papa-
georgiou General Hospital of Thessaloniki, Greece or
Medical Oncology of Aristotle University of Thessaloniki
in the same hospital, were enrolled in the study. Other
eligibility criteria included: a) preoperative MRI scan b)
WHO performance status of 2 or less c) adequate hemato-
logic, renal, and hepatic function (absolute neutrophil
count, ≥ 1500 per cubic millimeter; platelet count, ≥
100,000 per cubic millimeter; serum creatinine level, ≤ 1.5
times the upper limit of normal in the laboratory where it
was measured; total serum bilirubin level, ≤ 1.5 times the
upper limit of normal; and liver-function values, < 3 times
the upper limit of normal for the laboratory). The study
was approved by the Ethics committee of Aristotle Univer-
sity of Thessaloniki, Greece and written informed consent
was provided for every patient included.
Treatment
All patients received radiotherapy and chemotherapy
with Temozolomide. Radiotherapy was delivered using
linear accelerators with energy of 6 and/or 18 MV and
consisted of fractionated focal irradiation at a dose of 2
Gy per fraction given once daily five days per week over a
period of six weeks, for a total dose of 60 Gy. All patients
were treated supine and a thermoplastic mask was used
as an immobilization device. For all patients we used CT
simulation and the plan was performed with three-
dimensional planning systems. Target volumes were
based on postoperative MRIs. Two gross tumor volumes
(GTV) were defined. The initial GTV (GTV1) was
defined as T2 or FLAIR abnormality, including any
enhancement in T1 and the surgical cavity, and the boost
GTV (GTV2) as the contrast enhanced T1 abnormality,
including the surgical cavity. The corresponding clinical
target volumes (CTV1 and CTV2) and planning target
volumes (PTV1 and PTV2) were generated by adding 2
cm on the GTVs to account for sub-diagnostic infiltra-
tion and 0.5 cm on the CTVs to account for variations in
set-up and reproducibility, respectively. The initial target
volume (PTV1) was treated to 44 Gy and afterwards the
PTV2 for the rest 16 Gy, to a total of 60 Gy.
Chemotherapy with Temozolomide consisted of con-
current and adjuvant to radiation therapy phase in
accordance with the EORTC 26981/22981; NCIC CE3
intergroup trial [22], with slight variations. After com-
pletion of 6 cycles of chemotherapy it was at the investi-
gator’s discretion to continue for 6 more cycles
depending on response to the therapy.
MRI acquisition and volumetry
All patients underwent pre- and postoperative MRI (mag-
netic resonance imaging) scans. The postoperative MRI
scan was acquired one week before the initiation of radio-
therapy and at least 21 days after surgery, as we waited for
the acute postoperative abnormalities to subside.
For the purpose of volumetry, T1 and T2-weighted
MR sequences were used. Since the MR scans were not
available in an electronic format, but only in hard
copies, they were digitized, by means of a commercial
high-resolution scanner. Before determining tumor
volume with our specialized software, images were con-
verted to the widely used DICOM (Digital Imaging and
Communications in Medicine) format with a different
computer application. Our volumetric method was pre-
viously described in detail [23]. Briefly, the investigator
contoured the volume of interest (VOI) on each MR
slice. The software was able to calculate the volume of
the VOI using the following formula:
V=

Si ∗ z
Iliadis et al. BMC Cancer 2012, 12:3
http://www.biomedcentral.com/1471-2407/12/3
Page 2 of 13W h e r eVi st h ev o l u m eo ft h eV O I ,S i the surface
included by the contour of the VOI on each slice and z
the slice thickness. The accuracy of this method is
inversely proportional to slice thickness (Figure 1 and 2).
The volumes measured on preoperative MRIs were
necrosis, enhancing tumor (including any region of central
necrosis) and edema-T2 abnormality (including the
tumor) and on postoperative ones-prior to radioche-
motherapy (preRCT), net enhancing tumor. In the case of
multifocal lesions, the sum of all measurable lesions was
analyzed. All images were assessed by the same experi-
enced radiation oncologist. Volumetry was performed
before or during concurrent radiochemotherapy phase, as
we tried to avoid bias from retrospective evaluation.
Response evaluation and follow-up
During concurrent radiochemotherapy patients were eval-
uated weekly, clinically and with full blood counts and
blood chemistry tests. Twenty-one to 28 days after the
completion of the concurrent phase, patients underwent a
comprehensive evaluation including radiologic assessment
of the tumor with MRI. During adjuvant temozolomide
therapy, patients underwent a monthly clinical evaluation
and a comprehensive evaluation (including MRI) every 3
months until there was tumor progression or after two
years of follow-up and every 3-4 months thereafter. The
follow-up was updated on the May 4, 2010.
Tumor progression was defined according to MacDo-
nald’s response criteria [24]. When there was tumor pro-
gression patients were treated at their oncologist’s
discretion and the type of second-line therapy was recorded.
Toxic effects were graded according to the National Cancer
Institute Common Toxicity Criteria, version 3.0.
MGMT promoter methylation status, MGMT mRNA and
protein expression
Among the patients included in this study, formalin-fixed
paraffin embedded (FFPE) material from stereotactic
Figure 1 (a-g)-Example of contouring. Preoperative enhancing tumor in a glioblastoma patient.
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was available for analysis for 44 patients (tumor tissue
bank of the Hellenic Cooperative Oncology Group). The
a b o v et u m o r sw e r eu s e df o rT i s s u eM i c r o A r r a y( T M A )
construction (2 × 1.5 mm cores per tumor) and for DNA
and RNA extraction.
DNA and RNA extraction were accomplished on
manually microdissected whole sections at a total depth
of 40 um for RNA and of 60 um for DNA. DNA was
extracted with the QIAamp mini kit (Qiagen, Hilden,
Germany) and RNA with Trizol-LS (Invitrogen, Paisley,
UK) according to standard procedures. For first strand
cDNA synthesis the Superscript III system with random
primers and a final RNase H RNA removing step were
employed (all from Invitrogen). DNA samples were nor-
malized at 100 ng/ul, cDNA samples at 50 ng/ul; all
samples were stored at -20°C until use. DNA quality
was assessed with the multiplex PCR DNA control assay
from BIOMED2 and RNA quality was evaluated with
real time PCR (QRT-PCR) by employing a Taqman-
MGB assay for beta-glucuronidase (GUSB)a se n d o g e n -
ous control (assay ID: 4333767 F [Applied Biosystems]).
MGMT promoter methylation was evaluated with the
Multiplex Ligation-dependent Probe Amplification
(MLPA
®) and the SALSA MS-MLPA KIT ME011 test-
ing for methylation at three distinct CpG sites in the
MGMT enhancer. The procedure and the evaluation of
the results were accomplished according to the instruc-
tions of the manufacturer (MRC-Holland) and repeated
twice to assess concordance of results (retention of the
sample in the same category of methylation status). Eva-
luable results were yielded for 23/44 DNA tumor sam-
ples only (52.3%), all of which had amplification capacity
for ≥ 300 bp, as revealed with the multiplex DNA con-
trol test.
MGMT gene expression was assessed by using a pre-
made Taqman-MGB assay (Assay ID: Hs00172470_m1
[Applied Biosystems], ex 3-4, ref seq: NM_002412.3).
Runs were performed for sample duplicates and read-
ings were carried out at defa u l ts e t t i n g si na nA B I 7 5 0 0
real time PCR system equipped with the SDS v1.4 soft-
ware. Upon initial control for cDNA amplification capa-
city, 41/44 samples yielded CT (cycle threshold) values
≤ 29 for the endogenous control amplicon (GUSB,a s
described above). Relative expression was assessed as
the average 2^-dCT value (relative quantification value
[RQ]) based on equal PCR efficiencies for very short
amplicons [25] whereby dCT = MGMT CT-GUSB CT.
Individual RQ values did not differ by more than 0.8
arbitrary units between duplicates.
Immunohistochemistry (IHC) for MGMT was per-
formed on TMA sections of 2 um, using the monoclonal
Figure 2 Volumetry. Three-dimensional reconstruction of the volume, based on the regions of interest contoured in Figure 1. The number in
the left bottom corner represents the tumor volume in cc.
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Page 4 of 13antibody MAB16200 (Chemicon, clone: MT3.1, anti-
mouse), according to the instructions of the manufac-
turer (antigen retrieval: EDTA, dilution: 1:50). MGMT
protein expression was evaluated with two different cut-
offs, (a) 5% (absent ≤ 5%; present: > 5%) and (b) 20% (low
≤ 20%; high: > 20%) of tumor cells, respectively (modified
after [17,26]).
Statistical analysis
Categorical data are presented as frequencies and cor-
responding percentages, while continuous data are pre-
sented as median and range. 95% exact confidence
intervals using binomial distribution for treatment
responses are also given. For all measured volumes,
exploratory analysis was performed using the quartiles
of the corresponding distribution as predefined cut-
offs, testing their distinguishing ability in patient’s
prognosis. For each cut-off, tumors were categorized in
two categories (small vs. large volume). MGMT mRNA
expression was assessed as a continuous and MGMT
promoter methylation and protein expression as cate-
gorical variables.
Overall survival (OS) was measured from time of
operation to patient’s last contact or death. Progression
free survival (PFS) was measured from time of operation
to patient’s last contact, disease progression or death
from any cause without verified relapse. Time-to-event
distributions were estimated using the Kaplan-Meier
method and compared with the log-rank test. Univariate
Cox regression analysis was performed to examine the
prognostic significance of the examined volumetric or
MGMT related parameters. In the multivariate Cox ana-
lysis a backward selection procedure with removal cri-
terion p > 0.10, identified a subclass of significant
variables among the following: Sex (male vs. female), age
(< 50 vs > = 50), performance status (0 vs 1 or 2), type
of excision (partial/biopsy vs subtotal vs total), pre-
radiochemotherapy net enhancing tumor, preoperative
necrosis, preoperative T2 abnormality, and preoperative
enhancing tumor. For the categorisation of the type of
excision we used data from the surgeons based on their
impression during surgery and in some cases on post-
operative CT scans. It was categorised as total, subtotal
or partial/biopsy if there was resection of ≥ 99%, 75-99%
and < 75% of tumor volume, respectively. For all tests, a
= 0.05 level of significance was used. Analysis was con-
ducted using SPSS 15.
Results
Between July 2005 and August 2007, sixty-five patients
(37 males, 28 females), with a median age of 59 years
were assigned in our study. Patient’s characteristics at
the time of enrollment, along with tumor location, per-
formance status and tumor volumetric parameters are
shown in Table 1. All patients had surgical tissue diag-
nosis; 59 had undergone craniotomy and open biopsy
followed by maximal feasible tumor resection (13 total
resections, 33 subtotal resections and 13 partial resec-
tions or biopsies) and 6 received stereotactic biopsies.
Treatment delivery and toxicity
Treatment characteristics are shown in Table 2. One
patient prematurely discontinued both radiotherapy and
temozolomide due to severe hematologic toxic effects of
concomitant treatment and eight other patients did not
receive adjuvant temozolomide (2 due to death, 2 due to
progressive disease, 3 due to non-fatal toxic effects and
one due to patient refusal), although they had completed
concurrent treatment. Hematologic complications were
Table 1 Selected patient and tumor characteristics
N=6 5
Age (years) Median (range)
Median 59 (22-74)
N (%)
< 50 15 (23)
≥ 50 50 (77)
Sex
Male 37 (57)
Female 28 (43)
PS
0 34 (52)
1 25 (38)
2 6 (9)
Surgery
Partial/Biopsy* 19 (29)
Sutotal resection 33 (51)
Total resection 13 (20)
Hemisphere
Left 33 (51)
Right 29 (45)
Bilateral 3 (5)
Location
Temporal 20 (31)
Parietal 20 (31)
Occipital 3 (5)
Frontal 17 (26)
Deep 8 (12)
Volumetric parameters Median (range)
Enhancing tumor (cm
3) 34.7 (2.3-117.5)
Preoperative T2 abnormality (cm
3) 108.1 (3.8-230.9)
Necrosis (cm
3) 5.8 (0-57)
PreRCT Net-enhancing tumor (cm
3) 11 (0-80.8)
* 6 cases of stereotactic biopsy are included
Iliadis et al. BMC Cancer 2012, 12:3
http://www.biomedcentral.com/1471-2407/12/3
Page 5 of 13by far the most common. Overall, twenty-three patients
(35%) suffered from grade 3 or 4 hematologic toxicity.
More specifically, thrombocytopenia presented in 16
(25%), leucopenia in 13 (20%), neutropenia in 14 (22%)
and anemia in 1 (2%) of the patients. Regarding moderate
to severe non-hematologic complications, 3 patients pre-
sented with thromboembolic events and 3 other patients
suffered from pulmonary infections, one of whom died as
a consequence of pneumocystis carinii pneumonia.
Response and survival
Thirty-one patients (48%) responded to therapy; seven
of them completely (11%, 95% Confidence interval [CI]:
4.4-20.9) and twenty-four partially (37%, 95% CI: 25.3-
49.8). Twenty-seven patients had stable disease (42%,
95% CI: 29.4-54.4) and five developed progressive dis-
ease. Two patients were not evaluated for response due
to early tumor death and patient refusal.
After a median follow-up of 49.4 months, 61 patients
experienced disease progression, 58 died and 2 patients
were lost to follow-up. The median overall survival was
16.3 months (range 3.5-45.4 and 95% CI: 13.4-19.2) and
the first and second year survival rate was 74% and 32%,
respectively. The median progression-free survival was
9.5 months (range 2.8-35.8 and 95% CI: 6.8-12.1) and
the first and second year progression-free survival rate
was 38% and 11%, respectively. The corresponding
Kaplan-Meier curves are depicted on Figure 3.
Correlations of survival with clinical and volumetric
parameters
In the univariate Cox regression analysis, sex, age and
e x t e n to fs u r g e r yw e r en o tf o u n dt ob es t a t i s t i c a l l ys i g -
nificant predictors for OS or PFS, whereas PS was found
to influence both OS and PFS (Hazard ratio[HR] = 2.27,
95% CI:1.33-3.86; Wald’s p = 0.003 and HR = 2.45, 95%
CI:1.46-4.13; Wald’s p = 0.001, respectively).
Concerning the volumetric measurements (using con-
tinuous values), preoperative T2 abnormality was not
found to be a significant factor for survival or PFS,
while for the other parameters, we identified a 2%
excess risk of mortality for each one-unit increase in
pre-radiochemotherapy net-enhancing tumor volume
(HR = 1.02, 95% CI:1.01-1.04; Wald’s p = 0.001) and a
2% excess risk of progression for each one-unit increase
in preoperative necrosis volume (HR = 1.02, 95% CI:
1.00-1.05; Wald’s p = 0.021). Moreover, a 1% excess risk
of mortality and progression was observed for each one-
unit increase in preoperative enhancing tumor volume
Table 2 Treatment
Radiotherapy (RT)
Median total dose (range) 60 (48-60)
Median number of fractions (range) 30 (24-33)
Chemotherapy (CT)
· CT concomitant with RT 65 (100)
Total number of cycles delivered 417
Median number of cycles delivered (range) 7 (2-8)
· Adjuvant CT (post RT) 56 (86)
Total number of cycles delivered 343
Median number of cycles delivered (range) 6 (1-12)
Treatment status N (%)
Completed 31(48)
Discontinuation 34(52)
PD 19(29)
Death 5(8)
Toxicity (non fatal) 5(8)
Refused to continue 4(6)
Clinical deterioration 1(2)
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Figure 3 Overall survival (OS) (A) and progression-free survival (PFS) (B).
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Page 6 of 13(HR = 1.01, 95% CI: 1.00-1.02; Wald’s p = 0.037 and HR
= 1.01, 95% CI: 1.00-1.02; Wald’s p = 0.041, respectively)
(Table 3).
Furthermore, in the exploratory analysis a prognostic
threshold was detected for the preRCT net-enhancing
tumor volume regarding both OS and PFS (75th percen-
tile = 22,2 cm
3). Patients with large remaining tumor
postoperatively (preRCT net-enhancing tumor volume ≥
22.2 cm
3) had a reduced OS versus those with small
remaining tumor (log-rank p = 0.002). The HR for large
tumors was 2.59 (95% CI: 1.38-4.87, Wald’s p = 0.003). In
terms of PFS, large remaining tumors were associated
with shorter PFS (log-rank p = 0.002) and the HR was
2.64 (95% CI: 1.38-5.02, Wald’s p = 0.003) (Table 4 and 5
and Figure 4). For the rest of the volumes measured no
significant association was found in terms of OS or PFS.
Multivariate Cox regression analysis revealed that only
performance status and preRCT net-enhancing tumor
volume remained significant independent predictors of
OS, while performance status and preoperative necrosis
independently predicted PFS (Table 6). More specifi-
cally, preRCT net-enhancing tumor volume was asso-
ciated with an increased risk for death (HR = 1.02, 95%
CI: 1.00-1.04, Wald’s p = 0.023). As expected, perfor-
mance status of 1-2 was also associated with increased
risk for death (HR = 2.01, 95% CI: 1.15-3.51, Wald’s p =
0.014). Regarding PFS, preoperative necrosis and perfor-
mance status were associated with increased risk for dis-
ease progression (HR = 1.02, 95% CI: 1.00-1.04, Wald’s
p = 0.030 and HR = 2.88, 95% CI: 1.66-5.01, Wald’s p <
0.001 respectively).
MGMT assessments in association with volumetric
parameters and with patient outcome
Evaluation of MGMT mRNA expression was possible in
41/44 (93.2%), of MGMT protein expression in 35/44
(79.5%), and of MGMT promoter methylation status in
23/44 (52.3%) of the glioblastoma cases with available
tissue blocks. RQ values for MGMT mRNA ranged from
undetectable to 0.484 (mean: 0.028, ± SD: 0.075, med-
ian: 0.011). Ten out of 23 evaluable tumors (43.5%) were
found methylated for at least one target with MS-MLPA
(relative peak values > 0.25) and 13 tumors were
unmethylated (relative peak values ≤ 0.25); only 3/10
methylated tumors (approximately 13% of all evaluable
cases) were positive for all targets included in the assay
with relative peak values > 0.75, i.e. the threshold set for
the evaluation of complete methylation at the corre-
sponding sites [27]. MGMT IHC results are shown in
Table 7.
Although MGMT methylated tumors showed lower
mRNA expression, there was no statistically significant
association between the results of the three methods.
Neither MGMT promoter methylation nor MGMT
expression (mRNA/protein) showed statistically signifi-
cant association with patient PFS and OS.
In association with volumetric parameters, tumors
with a higher rate of MGMT protein expression (> 20%,
Table 3 Univariate Cox regression analysis of clinical factor and volume measurement with OS and PFS
Overall Survival Progression-free Survival
HR 95% CI p HR 95% CI p
Sex
Female 1 1
Male 1.18 0.69-2.02 0.538 1.32 0.79-2.23 0.289
Age
<5 0 1 1
≥ 50 1.54 0.83-2.89 0.174 1.43 0.77-2.67 0.259
PS
01 1
1 or 2 2.27 1.33-3.86 0.003 2.45 1.46-4.13 0.001
Surgery
Partial/Biopsy 1 1
Subtotal 2.02 0.95-4.32 0.069 0.96 0.53-1.73 0.881
Total 1.33 0.68-2.60 0.409 0.70 0.33-1.48 0.352
Volumetry
PreOp Enhancing tumor 1.01 1.00-1.02 0.037 1.01 1.00-1.02 0.041
PreOp T2 abnormality 1.00 1.00-1.01 0.276 1.00 1.00-1.01 0.387
PreOp Necrosis 1.02 1.00-1.04 0.067 1.02 1.00-1.05 0.021
PreRCT Net-enhancing tumor 1.02 1.01-1.04 0.001 1.01 1.00-1.02 0.068
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a lower rate of or negative for MGMT protein with IHC
(n = 11) (Mann-Whitney p = 0.021). MGMT parameters
were not associated with the rest of pre- or post-opera-
tive tumor volumetry parameters.
Discussion
In the present study we explored the prognostic signifi-
cance of several volumetric parameters for the progres-
sion-free and the overall survival in glioblastoma
patients. All patients were treated with the same radio-
chemotherapy scheme, in order to ensure the uniformity
of the population. Concerning the efficacy and toxicity
of the radiochemotherapy scheme our results are in
accordance with current literature [22,28].
As in most other studies dealing with glioblastoma
patients [29-32], we confirmed the importance of the
performance status as a factor influencing both survival
parameters. It is of note, however, that the extent of
resection was not found to be statistically significant.
This may be explained by the subjectivity of this parti-
cular assessment (surgeons’ impression and qualitative
rough estimation of postoperative CT images) and dic-
tates the need for the application of volumetry with
early (within 48 h) postoperative MRIs. We can further
assume, in this context, that the extent of resection may
not be significant, when it is expressed as a percentage
of the initial volume, but it is probably the absolute
volume of the tumor remnant, which is the determinant
factor affecting the prognosis.
The volumetric parameters, which were assessed in
this study, were the pre-radiochemotherapy net-enhan-
cing tumor volume and the preoperative enhancing
tumor, necrosis and T2-abnormality. We found that
pre-radiochemotherapy net-enhancing tumor volume
and preoperative volume of necrosis are significant pre-
dictors of outcome. Our results are consistent with prior
reports on the significance of volumetric parameters of
glioblastomas.
In a recent study reported by Saraswathy et al. [33]
the investigators evaluated the prognostic importance of
MR markers (anatomic, perfusion, diffusion and meta-
bolic) in pre-treatment (radiochemotherapy) scans in
patients with GBMs. They found that all of the above
parameters were associated with survival. In particular,
the volume of contrast enhancing lesion was inversely
correlated with survival.
In another study by Keles et al. [34] the authors con-
cluded that the volume of residual disease (VRD) at the
beginning of chemotherapy was a significant predictor
for both survival time and time to progression in
patients with recurrent glioblastomas. These patients,
however, were neither chemotherapy-naive, nor newly
diagnosed. In a different volumetric study of the same
group [35] evaluating the effect of extent of tumor
resection and VRD on survival, the authors reported
that both of these parameters influenced significantly
TTP and OS in patients with glioblastoma. This patient
group is not uniform, though, as they did not all receive
chemotherapy and the protocols are not noted. In addi-
tion, the volumetric measurements were not only per-
formed in MR scans but CT images, so the results are
not really comparable.
On the contrary, in the multivariate analysis of Tralins
et al., investigated the use of 18 F-FDG PET for the gui-
dance of radiation dose escalation in GBM patients, it
was found that only the volume of uptake and not the
volumes measured on MR images, including the T1-
Table 4 Median OS and PFS according to pre-radiochemotherapy net enhancing tumor volume
Events Median 95% CI Log-rank p
Overall Survival 0.002
Small (< 75th percentile = 22.2 cm
3) 44/49 20.10 15.24-24.96
Large (> = 75th percentile = 22.2 cm
3) 14/16 11.28 6.96-15.60
Progression-free Survival 0.002
Small (< 75th percentile = 22.2 cm
3) 46/49 11.70 7.70-15.71
Large (> = 75th percentile = 22.2 cm
3) 15/16 7.84 4.37-11.31
Log-rank test for overall and progression-free survival in association with large and small pre-radiochemotherapy net enhancing tumor volume
Table 5 Univariate Cox analysis of pre-radiochemotherapy net enhancing tumor volume with OS and PFS
Overall Survival Progression-free Survival
HR 95% CI p HR 95% CI p
PreRCT Net-enhancing tumor
Small (< 75th percentile = 22.2 cm
3)1- 1 -
Large (> 75th percentile = 22.2 cm
3) 2.59 1.38-4.87 0.003 2.64 1.38-5.02 0.003
Univariate Cox analysis for association of large and small pre-radiochemotherapy net enhancing tumor volume with overall survival and progression free survival
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Page 8 of 13weighted gadolinium enhancement, were of prognostic
significance for survival or time to progression [36].
That disagreement with our results could be explained
by the different time of MRI acquisition, since in the
above study it was performed during the course of
radiotherapy.
In a recent study of Cao et al. [37] the authors con-
cluded that only the vascular leakage volume measured
1-2 weeks prior radiation therapy in dynamic contrast
enhanced T2*-weighted images is of predictive value for
survival and not the volume of contrast enhanced lesion
measured in T1 weighted (nondynamic) images. How-
ever, in this study only patients with residual tumor
volume > 4 cm
3 were included and not all of the
patients received chemotherapy and that could explain
the discrepancy with our results.
At this point, we have to note that the prognostic value
of contrast enhancement has certain limitations. This has
been illustrated in a recent study by Piroth et al. [38],
correlating the volumetric findings of MRI with those of
positron emission tomography (PET) using O-(2-[(18)F]
fluoroethyl)-L-tyrosine (FET) and concluding that the lat-
ter has a stronger prognostic impact. To summarize,
although our study shows that pre-RCT net-enhancing
tumor has a prognostic value, the results from the litera-
ture are rather contradictory in this context.
Concerning the influence of preoperative enhancing
tumor volume, although it was found, in univariate
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Figure 4 Correlation of Overall survival (OS) (A) and progression-free survival (PFS) (B). Kaplan-Meyer curves for patients with large and
small pre-radiochemotherapy net enhancing tumor volume.
Table 6 Multivariate Cox Analysis
Overall Survival Progression-free Survival
HR 95% CI p HR 95% CI Wald-p
Age
<5 0 1 -
≥ 50 1.74 0.91-3.30 0.092
PS
01 - 1
1 or 2 2.01 1.15-3.51 0.014 2.88 1.66-5.01 < 0.001
Sex
Female 1
Male 1.61 0.93-2.79 0.090
PreOp Necrosis 1.02 1.00-1.04 0.030
PreOp Enhancing tumor 1.01 1.00-1.02 0.066
PreRCT Net-enhancing tumor 1.02 1.00-1.04 0.023
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Page 9 of 13analysis, to exert a negative impact on OS and PFS, this
effect disappeared when adjusted for other significant
predictors in the multivariate analysis. Our results are
almost identical with the results of Weber et al. [39] in
a study evaluating the prognostic factors in cerebellar
GBM. Similarly, in a large retrospective study from
Lacroix et al. [29] the multivariate analysis of 416
patients with GBM did not show any correlation of pre-
operative tumor volume with survival. There are numer-
ous other studies [40-42] supporting the lack of
prognostic importance of the preoperative enhancing
tumor volume. On the contrary, Xue et al. concluded
[43] that the accurate preoperative measurement of
tumor volume with computer-based three-dimensional
reconstruction is an important prognostic factor in
high-grade gliomas. The description of the regions of
interest that were delineated is not mentioned (contrast
enhancement, margins, edema etc.), and additionally,
the population of the study is not uniform, comprising
anaplastic astrocytomas and glioblastomas altogether.
The most logical explanation for the difference in
prognostic significance between pre and postoperative
enhancing volume is the variation of the extent of resec-
tion. Since extent of the resection is not primarily corre-
lated with the volume of the tumor, but with other
factors as well (e.g. location, infiltration of critical areas),
there is no distinct correlation between those two
volumes. We also have to take into consideration that a
variable period of time usually intervenes between the
operation and the initiation of treatment, during which
tumor re-growth may occur, thus rendering the pre-
treatment volume the most decisive factor for survival.
Necrosis is the imaging hallmark of GBM [44] and is
believed to indicate rapid growth and malignant beha-
vior [45]. We found that the volume of preoperative
necrosis is a significant independent prognostic factor
that negatively affects progression free survival, confirm-
ing several earlier studies pointing out this negative
impact [29,42]. In this context, it was interesting to
observe that tumors with a high rate of MGMT protein
positive tumor cells were significantly less necrotic, a
finding that may be related to the recently shown
decreased tumorigenicity of MGMT expressing cells in
preclinical models [46]. However, there are recent
volumetric studies that failed to show any correlation
between the absolute volume of necrosis and survival
[47-49]. Our finding suggests that large volume of
necrosis is indicative of a more aggressive phenotype,
which is also in accordance with the well established
pathological view that large necroses are associated with
sinister prognosis. Moreover, the necrotic core is asso-
ciated with hypoxia, which has been shown to be a fac-
tor of poor response to radio or chemotherapy, possibly
due to up-regulation of vascular endothelial growth fac-
tor (VEGF) expression that stimulates angiogenesis
[50-54]. To our knowledge there is no volumetric study
correlating the absolute volume of necrosis measured in
preoperative MR scan in glioblastoma patients with PFS.
Interestingly there was no correlation with overall survi-
val. This could be partially explained by the different
therapies following recurrence, as many of them con-
tained anti-VEGF agents, which would be more benefi-
cial for tumors with high VEGF levels [55].
T h el a s tp r e o p e r a t i v ev o l u m em e a s u r e dw a st h eT 2
abnormality (high intensity signal in T2-weighted MR
sequence). That volume includes the necrotic core, the
enhancing tumor and a perimetric zone, consisting of
vasogenic edema and tumor cells [56,57]. In our study
there was no association between that volume and PFS
or OS. This is in accordance with the results of Craw-
ford et al. [47] and Li et al. [49]. That result seems
straightforward since that volume includes a great
amount of edema, which is correlated with the dose of
the prescribed corticosteroids and, consequently, is not
a reliable measure of tumor burden.
Our study, certainly, points out that the precise
volume determination of anatomic parameters is still
essential in brain tumor research. It is simple, accurate,
cost-effective and easily applicable from most oncologi-
cal specialties. There are also several other imaging
modalities (perfusion and diffusion weighted MRI, pro-
ton MR spectroscopic imaging, PET-CT) which can play
a more significant role, maybe more important than the
volumetry of anatomic lesions [33,36,58-60]. More spe-
cifically, the use of amino acid tracers in PET has been
shown in recent studies to be superior compared to
MRI both in planning volumetric resection [61], as well
as in predicting the outcome of glioblastoma patients
prior and after RCT [38,62]. In addition, the significant
correlation of the pretreatment volume of enhancement
with overall survival, leads us to conclude that shorten-
ing (no longer than 6 weeks) of the interval between
surgery and initiation of radiochemotherapy could be of
great importance to survival, since it overcomes the pro-
blem of tumor regrowth [63]. This interval however, in
the light of data presented by Blumenthal et al. [64],
should not be earlier than 4 weeks allowing enough
Table 7 MGMT immunohistochemistry
n%
Evaluable results 35/44 79.5
MGMT absence (≤ 5% positive tumor cells) 18/35 51.4
MGMT presence (> 5% positive tumor cells) 17/35 48.6
Low MGMT expression (≤ 20% positive) 11/17 64.7
High MGMT expression (> 20% positive) 6/17 35.3
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Page 10 of 13time for recovery of the brain from the surgical injury
and edema.
T h e r ea r ec e r t a i n l ys o m ed r a w b a c k st h a tw en e e dt o
mention. As it has been pointed out in our previous
study [23], the lack of homogeneity in the MRI scans, as
well as the process of digitization, may cause several
variations in tumor delineation and the subsequently
determined volumes. In addition, as the MRI was not
performed during the optional time window of the first
48 h after surgery, visualization of the enhancing lesion
was probably affected by postoperative changes. More-
over, our analysis was based on a small sample size,
which may invoke the usual statistical uncertainties.
In this study, we did not observe any association of
MGMT related parameters with patient outcome. It
should be noticed, however, that the MLPA method
used to determine MGMT promoter methylation yielded
evaluable results in only half the samples available for
this investigation; the method works on paraffin tissue
extracts but it requires relatively preserved DNA, which
we only could obtain in a limited number of cases, as
evaluated by a multiplex control DNA PCR assay. In
comparison to the usually applied MSP-PCR, MLPA has
the advantage of providing information on the methyla-
tion status of multiple sites in the MGMT regulatory
region in a semi-quantitative manner [27]. The degree
of this epigenetic change seems to be of predictive
value, since tumors with incomplete MGMT promoter
methylation are reported to fail on temozolomide, while
those with complete methylation show a significant
trend to respond to this treatment [65]. The rate of
tumors with complete methylation in our series was
comparable to this report, but statistics could not be
performed since the absolute number of cases was low.
These results, as well as the lack of concordance among
MGMT promoter methylation status, mRNA and pro-
tein expression results, once again reflect the problems
encountered when assessing MGMT status on routine
histologic material, as already reported in previous com-
parative studies [66].
Conclusions
Our study showed that the volume of residual net-
enhancing tumor prior to radiochemotherapy signifi-
cantly affects survival in glioblastoma patients, although
relevant literature data are inconsistent. Additionally,
t h ev o l u m eo fp r e o p e r a t i v en e c r o s i ss e e m st ob eo f
prognostic significance for the PFS. The other preopera-
tive volumetric parameters studied (enhancing tumor,
T2 high signal abnormality) did not significantly affect
either OS or PFS. It is obvious that volumetry can still
play a significant role in defining patients who run a
greater risk if treated with conventional therapy (radio-
therapy plus temozolomide). For these patients,
alternative treatments should be sought and better stra-
tification for future studies could be achieved. A high
expression rate of MGMT protein in glioblastomas may
be related to a more indolent disease phenotype.
Acknowledgements
This work has been supported by a HeCOG research grant (TRANS_17/09)
and by a research grant from General Secretariat for Research and
Technology, Ministry of Development, Athens, Greece (PENED 3/583).
Author details
1Department of Radiation Oncology, “Papageorgiou” Hospital, Thessaloniki,
Greece.
2Department of Radiation Oncology, Interbalkan Medical Center,
Thessaloniki, Greece.
3Department of Pathology, Aristotle University of
Thessaloniki, School of Medicine, Thessaloniki, Greece.
4Department of
Neurosurgery, St Luke’s Hospital, Thessaloniki, Greece.
5Section of
Biostatistics, Hellenic Cooperative Oncology Group, Data Office, Athens,
Greece.
6Department of Medical Oncology, “Papageorgiou” Hospital, Aristotle
University of Thessaloniki, School of Medicine, Thessaloniki, Greece.
7Department of Neurosurgery, “AHEPA” Hospital, Aristotle University of
Thessaloniki, School of Medicine, Thessaloniki, Greece.
8Department of
Radiation Oncology, Interbalkan Medical Center, Asklipiou 10, 57001, Pylaia
Thessaloniki, Greece.
Authors’ contributions
GI was the primary investigator and wrote the manuscript and has
contributed in the enrolment of patients and treatment, VK carried out the
molecular genetic studies and contributed to the writing of the manuscript,
AC has been involved in drafting the manuscript, DT evaluated IHC stains,
AE performed the statistical analysis, SL has contributed to the acquisition of
data and the therapeutic management, DM and PS has contributed to the
initial design of the study, the enrolment of patients and treatment, GF has
made substantial contributions to the conception and design of the study
and to the enrolment of patients and the treatment. All the authors have
given final approval of the version to be published.
Competing interests
The authors declare that they have no competing interests.
Received: 12 July 2011 Accepted: 3 January 2012
Published: 3 January 2012
References
1. Welsh J, Sanan A, Gabayan AJ, Green SB, Lustig R, Burri S, Kwong E, Stea B:
GliaSite brachytherapy boost as part of initial treatment of glioblastoma
multiforme: a retrospective multi-institutional pilot study. Int J Radiat
Oncol Biol Phys 2007, 68(1):159-65, Epub 2007 Feb 27.
2. Panet-Raymond V, Souhami L, Roberge D, Kavan P, Shakibnia L, Muanza T,
Lambert C, Leblanc R, Del Maestro R, Guiot MC, Shenouda G: Accelerated
hypofractionated intensity-modulated radiotherapy with concurrent and
adjuvant temozolomide for patients with glioblastoma multiforme: a
safety and efficacy analysis. Int J Radiat Oncol Biol Phys 2009, 73(2):473-8,
Epub 2008 Jun 12.
3. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M,
Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L, Mehta MP,
Curran WJ Jr: Randomized comparison of stereotactic radiosurgery
followed by conventional radiotherapy with carmustine to conventional
radiotherapy with carmustine for patients with glioblastoma multiforme:
report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat
Oncol Biol Phys 2004, 60(3):853-60.
4. Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, Schultz C,
Souhami L, Chen A, Pham H, Mehta M: A phase II trial of accelerated
radiotherapy using weekly stereotactic conformal boost for
supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol
Biol Phys 2006, 65(5):1422-8, Epub 2006 Jun 5.
5. Laperriere NJ, Leung PM, McKenzie S, Milosevic M, Wong S, Glen J,
Pintilie M, Bernstein M: Randomized study of brachytherapy in the initial
management of patients with malignant astrocytoma. Int J Radiat Oncol
Biol Phys 1998, 41(5):1005-11.
Iliadis et al. BMC Cancer 2012, 12:3
http://www.biomedcentral.com/1471-2407/12/3
Page 11 of 136. Nieder C, Andratschke N, Wiedenmann N, Busch R, Grosu AL, Molls M:
Radiotherapy for high-grade gliomas. Does altered fractionation improve
the outcome. Strahlenther Onkol 2004, 180(7):401-7, Review.
7. Grabenbauer GG, Gerber KD, Ganslandt O, Richter A, Klautke G, Birkmann J,
Meyer M: Effects of concurrent topotecan and radiation on 6-month
progression-free survival in the primary treatment of glioblastoma
multiforme. Int J Radiat Oncol Biol Phys 2009, 75(1):164-9.
8. Colman H, Berkey BA, Maor MH, Groves MD, Schultz CJ, Vermeulen S,
Nelson DF, Mehta MP, Yung WK, Radiation Therapy Oncology Group: Phase
II Radiation Therapy Oncology Group trial of conventional radiation
therapy followed by treatment with recombinant interferon-beta for
supratentorial glioblastoma: results of RTOG 9710. Int J Radiat Oncol Biol
Phys 2006, 66(3):818-24, Epub 2006 Aug 2.
9. Plataniotis GA, Theofanopoulou ME, Kalogera-Fountzila A, Haritanti A,
Ciuleanou E, Ghilezan N, Zamboglou N, Dimitriadis A, Sofroniadis I,
Fountzilas G: Prognostic impact of tumor volumetry in patients with
locally advanced head-and-neck carcinoma (non-nasopharyngeal)
treated by radiotherapy alone or combined radiochemotherapy in a
randomized trial. Int J Radiat Oncol Biol Phys 2004, 59(4):1018-26.
10. Kurek R, Kalogera-Fountzila A, Muskalla K, Dafni U, Schnabel T, Kober B,
Roddiger S, Martin T, Fountzilas G, Zamboglou N: Usefulness of tumor
volumetry as a prognostic factor of survival in head and neck cancer.
Strahlenther Onkol 2003, 179(5):292-7.
11. Johnson CR, Khandelwal SR, Schmidt-Ullrich RK, Ravalese J, Wazer DE: The
influence of quantitative tumor volume measurements on local control
in advanced head and neck cancer using concomitant boost
accelerated superfractionated irradiation. Int J Radiat Oncol Biol Phys 1995,
32(3):635-41.
12. Rudat V, Dietz A, Schramm O, Conradt C, Maier H, Flentje M,
Wannenmacher M: Prognostic impact of total tumor volume and
hemoglobin concentration on the outcome of patients with advanced
head and neck cancer after concomitant boost radiochemotherapy.
Radiother Oncol 1999, 53(2):119-25.
13. Andreopoulou E, Andreopoulos D, Adamidis K, Fountzila-Kalogera A,
Fountzilas G, Dimopoulos MA, Aravantinos G, Zamboglou N, Baltas D,
Pavlidis N: Tumor volumetry as predictive and prognostic factor in the
management of ovarian cancer. Anticancer Res 2002, 22(3):1903-8.
14. Burghardt E, Baltzer J, Tulusan AH, Haas J: Results of surgical treatment of
1028 cervical cancers studied with volumetry. Cancer 1992, 70(3):648-55.
15. Kikuchi S, Sakuramoto S, Kobayashi N, Shimao H, Sakakibara Y, Sato K,
Kakita A: Tumor volumetry: proposal of a new concept to predict lymph
node metastasis in early gastric cancer. Anticancer Res 2000,
20(5C):3669-74.
16. Stupp R, Roila F, ESMO Guidelines Working Group: Malignant glioma:
ESMO clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol 2009, 20(Suppl 4):126-8, Review.
17. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF,
Vanaclocha V, Baylin SB, Herman JG: Inactivation of the DNA-repair gene
MGMT and the clinical response of gliomas to alkylating agents. N Engl J
Med 2000, 343(19):1350-4, Erratum in: N Engl J Med 2000 Dec 7;343
(23):1740.
18. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC,
Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J,
Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T,
Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation
for Research and Treatment of Cancer Brain Tumour and Radiation
Oncology Groups; National Cancer Institute of Canada Clinical Trials Group:
Effects of radiotherapy with concomitant and adjuvant temozolomide
versus radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol
2009, 10(5):459-66, Epub 2009 Mar 9.
19. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG,
Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R:
Nomograms for predicting survival of patients with newly diagnosed
glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-
22981/CE.3. Lancet Oncol 2008, 9(1):29-38, Epub 2007 Dec 21.
20. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W,
Hegi ME: MGMT promoter methylation in malignant gliomas: ready for
personalized medicine. Nat Rev Neurol 2010, 6(1):39-51, Epub 2009 Dec 8.
Review.
21. Brell M, Tortosa A, Verger E, Gil JM, Viñolas N, Villá S, Acebes JJ, Caral L,
Pujol T, Ferrer I, Ribalta T, Graus F: Prognostic significance of O6-
methylguanine-DNA methyltransferase determined by promoter
hypermethylation and immunohistochemical expression in anaplastic
gliomas. Clin Cancer Res 2005, 11(14):5167-74.
22. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ,
Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC,
Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E,
Mirimanoff RO, European Organisation for Research and Treatment of
Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of
Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-96.
23. Iliadis G, Selviaridis P, Kalogera-Fountzila A, Fragkoulidi A, Baltas D, Tselis N,
Chatzisotiriou A, Misailidou D, Zamboglou N, Fountzilas G: The importance
of tumor volume in the prognosis of patients with glioblastoma:
Comparison of computerized volumetry and geometrical models.
Strahlenther Onkol 2009, 185(11):743-50, Epub 2009 Nov 10.
24. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria
for phase II studies of malignant glioma. J Clin Oncol 1990, 8:1277-80.
25. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
2001, 25(4):402-8.
26. Capper D, Mittelbronn M, Meyermann R, Schittenhelm J: Pitfalls in the
assessment of MGMT expression and in its correlation with survival in
diffuse astrocytomas: proposal of a feasible immunohistochemical
approach. Acta Neuropathol 2008, 115(2):249-59, Epub 2007 Oct 27.
27. Jeuken JW, Cornelissen SJ, Vriezen M, Dekkers MM, Errami A, Sijben A,
Boots-Sprenger SH, Wesseling P: MS-MLPA: an attractive alternative
laboratory assay for robust, reliable, and semiquantitative detection of
MGMT promoter hypermethylation in gliomas. Lab Invest 2007,
87(10):1055-65, Epub 2007 Aug 13.
28. Nieder C, Adam M, Grosu AL: Combined modality treatment of
glioblastoma multiforme: the role of temozolomide. Rev Recent Clin Trials
2006, 1(1):43-51, Review.
29. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F,
Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C,
Miller D, Sawaya R: A multivariate analysis of 416 patients with
glioblastoma multiforme: prognosis, extent of resection, and survival. J
Neurosurg 2001, 95(2):190-8.
30. Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, Lillehei KO,
Bernstein M, Brem H, Sloan A, Berger MS: Chang S; Glioma Outcomes
Investigators: Survival following surgery and prognostic factors for
recently diagnosed malignant glioma: data from the Glioma Outcomes
Project. J Neurosurg 2003, 99(3):467-73.
31. Hentschel SJ, Sawaya R: Optimizing outcomes with maximal surgical
resection of malignant gliomas. Cancer Control 2003, 10(2):109-14, Review.
32. Ammirati M, Vick N, Liao YL, Ciric I, Mikhael M: Effect of the extent of
surgical resection on survival and quality of life in patients with
supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery
1987, 21(2):201-6.
33. Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S,
Nelson SJ: Evaluation of MR markers that predict survival in patients
with newly diagnosed GBM prior to adjuvant therapy. J Neurooncol 2009,
91(1):69-81, Epub 2008 Sep 23.
34. Keles GE, Lamborn KR, Chang SM, Prados MD, Berger MS: Volume of
residual disease as a predictor of outcome in adult patients with
recurrent supratentorial glioblastomas multiforme who are undergoing
chemotherapy. J Neurosurg 2004, 100(1):41-6.
35. Keles GE, Anderson B, Berger MS: The effect of extent of resection on
time to tumor progression and survival in patients with glioblastoma
multiforme of the cerebral hemisphere. Surg Neurol 1999, 52(4):371-9.
36. Tralins KS, Douglas JG, Stelzer KJ, Mankoff DA, Silbergeld DL, Rostomily RC,
Hummel S, Scharnhorst J, Krohn KA, Spence AM: Volumetric analysis of 18
F-FDG PET in glioblastoma multiforme: prognostic information and
possible role in definition of target volumes in radiation dose escalation.
J Nucl Med 2002, 43(12):1667-73.
37. Cao Y, Nagesh V, Hamstra D, Tsien CI, Ross BD, Chenevert TL, Junck L,
Lawrence TS: The extent and severity of vascular leakage as evidence of
tumor aggressiveness in high-grade gliomas. Cancer Res 2006,
66(17):8912-7.
Iliadis et al. BMC Cancer 2012, 12:3
http://www.biomedcentral.com/1471-2407/12/3
Page 12 of 1338. Piroth MD, Holy R, Pinkawa M, Stoffels G, Kaiser HJ, Galldiks N, Herzog H,
Coenen HH, Eble MJ, Langen KJ: Prognostic impact of postoperative, pre-
irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients
treated with radiochemotherapy. Radiother Oncol 2011, 99(2):218-24, Epub
2011 Apr 16.
39. Weber DC, Miller RC, Villà S, Hanssens P, Baumert BG, Castadot P, Varlet P,
Abacioglu U, Igdem S, Szutowicz E, Nishioka H, Hofer S, Rutz HP,
Ozsahin M, Taghian A, Mirimanoff RO: Outcome and prognostic factors in
cerebellar glioblastoma multiforme in adults: a retrospective study from
the Rare Cancer Network. Int J Radiat Oncol Biol Phys 2006, 66(1):179-86,
Epub 2006 Jul 11.
40. Wang YY, Yang GK, Li SY, Baol XF, Wu CY: Prognostic factors for deep
situated malignant gliomas treated with linac radiosurgery. Chin Med Sci
J 2004, 19(2):105-10.
41. Kowalczuk A, Macdonald RL, Amidei C, Dohrmann G, Erickson RK,
Hekmatpanah J, Krauss S, Krishnasamy S, Masters G, Mullan SF, Mundt AJ,
Sweeney P, Vokes EE, Weir BK, Wollman RL: Quantitative imaging study of
extent of surgical resection and prognosis of malignant astrocytomas.
Neurosurgery 1997, 41(5):1028-36, discussion 1036-8.
42. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE: Prognostic
significance of preoperative MRI scans in glioblastoma multiforme. J
Neurooncol 1996, 27(1):65-73.
43. Xue D, Albright RE Jr: Preoperative anaplastic glioma tumor volume
effects on patient survival. J Surg Oncol 1999, 72(4):199-205.
44. Burger PC, Heinz ER, Shibata T, Kleihues P: Topographic anatomy and CT
correlations in the untreated glioblastoma multiforme. J Neurosurg 1988,
68(5):698-704.
45. Segall HD, Destian S, Nelson MD Jr, et al: CT and MR imaging in
malignant gliomas. In Malignant Cerebral Glioma. Edited by: Apuzzo MLJ.
Park Ridge, IL: American Association of Neurological Surgeons; 1990:63-77.
46. Chahal M, Xu Y, Lesniak D, Graham K, Famulski K, Christensen JG, Aghi M,
Jacques A, Murray D, Sabri S, Abdulkarim B: MGMT modulates
glioblastoma angiogenesis and response to the tyrosine kinase inhibitor
sunitinib. Neuro Oncol 2010, 12(8):822-33, Epub 2010 Feb 23.
47. Crawford FW, Khayal IS, McGue C, Saraswathy S, Pirzkall A, Cha S,
Lamborn KR, Chang SM, Berger MS, Nelson SJ: Relationship of
preoperative metabolic and physiological MR imaging parameters to
survival for patients with untreated GBM. J Neurooncol 2009, 91(3):337-51,
Epub 2008 Nov 15.
48. Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, Owens J, Ellsworth GB,
Salzman KL, Kinney AY, Jensen RL: Hypoxia-regulated protein expression,
patient characteristics, and preoperative imaging as predictors of
survival in adults with glioblastoma multiforme. Cancer 2008,
113(5):1032-42.
49. Li X, Jin H, Lu Y, Oh J, Chang S, Nelson SJ: Identification of MRI and 1H
MRSI parameters that may predict survival for patients with malignant
gliomas. NMR Biomed 2004, 17(1):10-20.
50. Raza SM, Lang FF, Aggarwal BB, Fuller GN, Wildrick DM, Sawaya R: Necrosis
and glioblastoma: a friend or a foe? A review and a hypothesis.
Neurosurgery 2002, 51(1):2-12, discussion 12-3. Review.
51. D’ Angelo MG, Afanasieva T, Aguzzi A: Angiogenesis in transgenic models
of multistep carcinogenesis. J Neurooncol 2000, 50(1-2):89-98, Review.
52. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor
induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature
1992, 359:843-845.
53. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor
is a potential tumour angiogenesis factor in human gliomas in vivo.
Nature 1992, 359:845-848.
54. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG: Hypoxia
and the hypoxia-inducible-factor pathway in glioma growth and
angiogenesis. Neuro Oncol 2005, 7:134-153.
55. Chamberlain MC: Emerging clinical principles on the use of bevacizumab
for the treatment of malignant gliomas. Cancer 2010, 116(17):3988.
56. Earnest F, Kelly PJ, Scheithauer BW, Kall BA, Cascino TL, Ehman RL,
Forbes GS, Axley PL: Cerebral astrocytomas: histopathologic correlation of
MR and CT contrast enhancement with stereotactic biopsy. Radiology
1988, 166(3):823-7.
57. Kelly PJ, Daumas-Duport C, Scheithauer BW, Kall BA, Kispert DB: Stereotactic
histologic correlations of computed tomography-and magnetic
resonance imaging-defined abnormalities in patients with glial
neoplasms. Mayo Clin Proc 1987, 62(6):450-9.
58. Oh J, Henry RG, Pirzkall A, Lu Y, Li X, Catalaa I, Chang S, Dillon WP,
Nelson SJ: Survival analysis in patients with glioblastoma multiforme:
predictive value of choline-to-N-acetylaspartate index, apparent
diffusion coefficient, and relative cerebral blood volume. J Magn Reson
Imaging 2004, 19(5):546-54.
59. Pirzkall A, Li X, Oh J, Chang S, Berger MS, Larson DA, Verhey LJ, Dillon WP,
Nelson SJ: 3D MRSI for resected high-grade gliomas before RT: tumor
extent according to metabolic activity in relation to MRI. Int J Radiat
Oncol Biol Phys 2004, 59(1):126-37.
60. Thiele F, Ehmer J, Piroth MD, Eble MJ, Coenen HH, Kaiser HJ, Schaefer WM,
Buell U, Boy C: The quantification of dynamic FET PET imaging and
correlation with the clinical outcome in patients with glioblastoma. Phys
Med Biol 2009, 54(18):5525-39, Epub 2009 Aug.
61. Pirotte BJ, Levivier M, Goldman S, Massager N, Wikler D, Dewitte O,
Bruneau M, Rorive S, David P, Brotchi J: Positron emission tomography-
guided volumetric resection of supratentorial high-grade gliomas: a
survival analysis in 66 consecutive patients. Neurosurgery 2009,
64(3):471-81, discussion 481.
62. Piroth MD, Pinkawa M, Holy R, Klotz J, Nussen S, Stoffels G, Coenen HH,
Kaiser HJ, Langen KJ, Eble MJ: Prognostic value of early [18 F]
fluoroethyltyrosine positron emission tomography after
radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol
Phys 2011, 80(1):176-84, Epub 2010 Jun 18.
63. Pirzkall A, McGue C, Saraswathy S, Cha S, Liu R, Vandenberg S, Lamborn KR,
Berger MS, Chang SM, Nelson SJ: Tumor regrowth between surgery and
initiation of adjuvant therapy in patients with newly diagnosed
glioblastoma. Neuro Oncol 2009, 11(6):842-52, Epub.
64. Blumenthal DT, Won M, Mehta MP, Curran WJ, Souhami L, Michalski JM,
Rogers CL, Corn BW: Short delay in initiation of radiotherapy may not
affect outcome of patients with glioblastoma: a secondary analysis from
the radiation therapy oncology group database. J Clin Oncol 2009,
27(5):733-9, Epub 2008 Dec 29.
65. Martinez R, Martin-Subero JI, Rohde V, Kirsch M, Alaminos M, Fernandez AF,
Ropero S, Schackert G, Esteller M: A microarray-based DNA methylation
study of glioblastoma multiforme. Epigenetics 2009, 4(4):255-64, Epub 2009
May 29.
66. Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goeppert M,
Steiger HJ, Friedensdorf B, Reifenberger G, Sabel MC: Prognostic
significance of molecular markers and extent of resection in primary
glioblastoma patients. Clin Cancer Res 2009, 15(21):6683-93, Epub 2009 Oct
27.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/12/3/prepub
doi:10.1186/1471-2407-12-3
Cite this article as: Iliadis et al.: Volumetric and MGMT parameters in
glioblastoma patients: Survival analysis. BMC Cancer 2012 12:3.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Iliadis et al. BMC Cancer 2012, 12:3
http://www.biomedcentral.com/1471-2407/12/3
Page 13 of 13